0540544 - BC 2021 RIV CH eng J - Journal Article
Štefánik, M. - Valdés, James J. - Ezebuo, F.C. - Haviernik, J. - Uzochukwu, I.C. - Fojtiková, M. - Salát, J. - Eyer, Luděk - Růžek, Daniel
FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells.
Microorganisms. Roč. 8, č. 4 (2020), č. článku 599. E-ISSN 2076-2607
R&D Projects: GA MZd(CZ) NV16-34238A
Institutional support: RVO:60077344
Keywords : nucleoside inhibitors * virus * protein * screen * pele * fda * flavivirus * Zika virus * tick-borne encephalitis virus * West Nile virus * antiviral
OECD category: Microbiology
Impact factor: 4.128, year: 2020
Method of publishing: Open access
https://www.mdpi.com/2076-2607/8/4/599
Permanent Link: http://hdl.handle.net/11104/0318171
Štefánik, M. - Valdés, James J. - Ezebuo, F.C. - Haviernik, J. - Uzochukwu, I.C. - Fojtiková, M. - Salát, J. - Eyer, Luděk - Růžek, Daniel
FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells.
Microorganisms. Roč. 8, č. 4 (2020), č. článku 599. E-ISSN 2076-2607
R&D Projects: GA MZd(CZ) NV16-34238A
Institutional support: RVO:60077344
Keywords : nucleoside inhibitors * virus * protein * screen * pele * fda * flavivirus * Zika virus * tick-borne encephalitis virus * West Nile virus * antiviral
OECD category: Microbiology
Impact factor: 4.128, year: 2020
Method of publishing: Open access
https://www.mdpi.com/2076-2607/8/4/599
Permanent Link: http://hdl.handle.net/11104/0318171